Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Invocare (IVC.AX)

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (A$)	Price Target (A$)	Rating
2020-07-31	9.55	11.85	Neutral
2020-08-21	10.23	10.75	Neutral
2020-11-12	11.64	11.30	Neutral
2021-02-26	11.23	11.00	Neutral
2021-05-28	10.55	10.30	Neutral
2021-08-30	12.15	12.10	Neutral
2022-02-28	12.93	13.00	Neutral
2022-05-20	12.09	12.40	Neutral
2022-08-30	11.27	11.60	Neutral
2023-02-28	9.50	8.85	Sell
2023-03-07	12.08	-	No Rating

Disclosures

UBS Securities Australia Ltd is acting as advisor to TPG on a potential acquisition of Invocare Limited (IVC.AX) and will receive a fee for these services.
UBS beneficially owned 1% or more of a class of this company`s common equity securities as of last month`s end (or the prior month`s end if this report is dated less than 10 days after the most recent month`s end).

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day.